Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, phase 2 trial to explore the efficacy and safety of the
combination of lenalidomide and R-CHOP for preventing the CNS relapse in the high-risk
diffuse large B cell lymphoma.